Managing Potential Drug Interactions of Nirmatrelvir/Ritonavir in COVID-19 Patients: A Perspective from an Israeli Cross-Sector Collaboration

Shiri Guy-Alfandary; Sasha Zhurat; Maya Berlin; Tal De Haan; Itai Gueta; Renata Shihmanter; Ahuva Golik; Matitiahu Berkovitch; Sara Eyal; Lee H. Goldstein

doi:10.1002/cpt.2610

Managing Potential Drug Interactions of Nirmatrelvir/Ritonavir in COVID-19 Patients: A Perspective from an Israeli Cross-Sector Collaboration

Shiri Guy-Alfandary, Sasha Zhurat, Maya Berlin, Tal De Haan, Itai Gueta, Renata Shihmanter, Ahuva Golik, Matitiahu Berkovitch, Sara Eyal, Lee H. Goldstein

Tel Aviv University, Ariel University, The Hebrew University of Jerusalem, Technion - Israel Institute of Technology

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	1156-1158
Number of pages	3
Journal	Clinical Pharmacology and Therapeutics
Volume	112
Issue number	6
DOIs	https://doi.org/10.1002/cpt.2610
State	Published - Dec 2022

Keywords

COVID-19 Drug Treatment
Drug Interactions
Humans
Israel/epidemiology
Ritonavir/therapeutic use

All Science Journal Classification (ASJC) codes

Pharmacology
Pharmacology (medical)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/cpt.2610

Cite this

Guy-Alfandary, S., Zhurat, S., Berlin, M., De Haan, T., Gueta, I., Shihmanter, R., Golik, A., Berkovitch, M., Eyal, S., & Goldstein, L. H. (2022). Managing Potential Drug Interactions of Nirmatrelvir/Ritonavir in COVID-19 Patients: A Perspective from an Israeli Cross-Sector Collaboration. Clinical Pharmacology and Therapeutics, 112(6), 1156-1158. https://doi.org/10.1002/cpt.2610

@article{e1df1268cc7244f986fcc9b4ad9156b5,

title = "Managing Potential Drug Interactions of Nirmatrelvir/Ritonavir in COVID-19 Patients: A Perspective from an Israeli Cross-Sector Collaboration",

keywords = "COVID-19 Drug Treatment, Drug Interactions, Humans, Israel/epidemiology, Ritonavir/therapeutic use",

author = "Shiri Guy-Alfandary and Sasha Zhurat and Maya Berlin and {De Haan}, Tal and Itai Gueta and Renata Shihmanter and Ahuva Golik and Matitiahu Berkovitch and Sara Eyal and Goldstein, {Lee H.}",

note = "Funding Information: This perspective received no funding. The authors acknowledge the helpful input of Mg. Hadas Rotem, M. Sc., and Dr. Einat Gorelik, Pharm.D., from the Israeli MOH.",

year = "2022",

month = dec,

doi = "10.1002/cpt.2610",

language = "الإنجليزيّة",

volume = "112",

pages = "1156--1158",

journal = "Clinical Pharmacology and Therapeutics",

issn = "0009-9236",

publisher = "Wiley-Blackwell",

number = "6",

}

Guy-Alfandary, S, Zhurat, S, Berlin, M, De Haan, T, Gueta, I, Shihmanter, R, Golik, A, Berkovitch, M, Eyal, S & Goldstein, LH 2022, 'Managing Potential Drug Interactions of Nirmatrelvir/Ritonavir in COVID-19 Patients: A Perspective from an Israeli Cross-Sector Collaboration', Clinical Pharmacology and Therapeutics, vol. 112, no. 6, pp. 1156-1158. https://doi.org/10.1002/cpt.2610

TY - JOUR

T1 - Managing Potential Drug Interactions of Nirmatrelvir/Ritonavir in COVID-19 Patients

T2 - A Perspective from an Israeli Cross-Sector Collaboration

AU - Guy-Alfandary, Shiri

AU - Zhurat, Sasha

AU - Berlin, Maya

AU - De Haan, Tal

AU - Gueta, Itai

AU - Shihmanter, Renata

AU - Golik, Ahuva

AU - Berkovitch, Matitiahu

AU - Eyal, Sara

AU - Goldstein, Lee H.

N1 - Funding Information: This perspective received no funding. The authors acknowledge the helpful input of Mg. Hadas Rotem, M. Sc., and Dr. Einat Gorelik, Pharm.D., from the Israeli MOH.

PY - 2022/12

Y1 - 2022/12

KW - COVID-19 Drug Treatment

KW - Drug Interactions

KW - Humans

KW - Israel/epidemiology

KW - Ritonavir/therapeutic use

UR - http://www.scopus.com/inward/record.url?scp=85129879230&partnerID=8YFLogxK

U2 - 10.1002/cpt.2610

DO - 10.1002/cpt.2610

M3 - مقالة

C2 - 35521643

SN - 0009-9236

VL - 112

SP - 1156

EP - 1158

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

IS - 6

ER -

Managing Potential Drug Interactions of Nirmatrelvir/Ritonavir in COVID-19 Patients: A Perspective from an Israeli Cross-Sector Collaboration

Keywords

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Cite this